Effect of conditioning regimen intensity on disease-free survival, relapse, nonrelapse mortality, and survival: AML and MDS only
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Disease-free survival* | |||
| Age, 18-54 y | |||
| Myeloablative | 121/258 | 1.00 | |
| Reduced intensity | 130/212 | 1.44 (1.12-1.86) | .004 |
| Age, 55-70 y | |||
| Myeloablative | 81/130 | 1.00 | |
| Reduced intensity | 265/433 | 0.94 (0.73-1.22) | .66 |
| Relapse† | |||
| Age, 18-54 y | |||
| Myeloablative | 81/258 | 1.00 | |
| Reduced intensity | 93/212 | 1.54 (1.14-2.10) | .005 |
| Age, 55-70 y | |||
| Myeloablative | 41/130 | 1.00 | |
| Reduced intensity | 181/433 | 1.25 (0.89-1.76) | .21 |
| Nonrelapse mortality‡ | |||
| Age, 18-54 y | |||
| Myeloablative | 40/258 | 1.00 | |
| Reduced intensity | 37/212 | 1.24 (0.79-2.00) | .36 |
| Age, 55-70 y | |||
| Myeloablative | 40/130 | 1.00 | |
| Reduced intensity | 84/433 | 0.63 (0.43-0.93) | .02 |
| Overall survival§ | |||
| Age, 18-54 y | |||
| Myeloablative | 105/259 | 1.00 | |
| Reduced intensity | 110/214 | 1.35 (1.04-1.77) | .027 |
| Age, 55-70 y | |||
| Myeloablative | 76/131 | 1.00 | |
| Reduced intensity | 241/435 | 0.84 (0.65-1.09) | .18 |
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Disease-free survival* | |||
| Age, 18-54 y | |||
| Myeloablative | 121/258 | 1.00 | |
| Reduced intensity | 130/212 | 1.44 (1.12-1.86) | .004 |
| Age, 55-70 y | |||
| Myeloablative | 81/130 | 1.00 | |
| Reduced intensity | 265/433 | 0.94 (0.73-1.22) | .66 |
| Relapse† | |||
| Age, 18-54 y | |||
| Myeloablative | 81/258 | 1.00 | |
| Reduced intensity | 93/212 | 1.54 (1.14-2.10) | .005 |
| Age, 55-70 y | |||
| Myeloablative | 41/130 | 1.00 | |
| Reduced intensity | 181/433 | 1.25 (0.89-1.76) | .21 |
| Nonrelapse mortality‡ | |||
| Age, 18-54 y | |||
| Myeloablative | 40/258 | 1.00 | |
| Reduced intensity | 37/212 | 1.24 (0.79-2.00) | .36 |
| Age, 55-70 y | |||
| Myeloablative | 40/130 | 1.00 | |
| Reduced intensity | 84/433 | 0.63 (0.43-0.93) | .02 |
| Overall survival§ | |||
| Age, 18-54 y | |||
| Myeloablative | 105/259 | 1.00 | |
| Reduced intensity | 110/214 | 1.35 (1.04-1.77) | .027 |
| Age, 55-70 y | |||
| Myeloablative | 76/131 | 1.00 | |
| Reduced intensity | 241/435 | 0.84 (0.65-1.09) | .18 |
Lower disease-free survival for patients with comorbidity score ≥3 compared with ≤2 (HR, 1.26; 95% CI, 1.07-1.48; P = .0049) and high disease risk index compared with low disease risk index (HR, 1.97; 95% CI, 1.27-3.03; P = .002) and intermediate disease risk index (HR, 1.94; 95% CI, 1.64-2.31; P < .001). Graft type was not associated with an increased risk of disease-free survival (HR, 1.09; 95% CI, 0.93-1.30; P = .27).
Higher relapse for patients with high disease risk index (HR, 2.13; 95% CI, 1.72-2.64; P < .001). Relapse was lower for patients with MDS compared with AML (HR, 0.67; 95% CI, 0.52-0.88; P = .004) and transplant of peripheral blood compared with bone marrow (HR, 0.80; 95% CI, 0.65-0.98; P = .03). Comorbidity score ≥3 was not associated with an increased risk of relapse (HR, 1.08; 95% CI, 0.89-1.32; P = .43).
Higher nonrelapse mortality for patients with comorbidity score ≥3 compared with ≤2 (HR, 1.71; 95% CI, 1.28-2.82; P = .0003) and high disease risk index compared with intermediate disease risk index (HR, 1.63; 95% CI, 1.19-2.22; P = .0019).
Lower overall survival for patients with comorbidity score ≥3compared with ≤2 (HR, 1.31; 95% CI, 1.10-1.56; P = .002), CMV seropositivity (HR, 1.34; 95% CI, 1.11-1.62; P = .03), and high disease risk index compared with low disease risk index (HR, 2.29; 95% CI, 1.37-3.82; P = .001) and intermediate disease risk index (HR, 1.87; 95% CI, 1.56-2.24; P < .001).